Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 4067 results found since Jan 2013.

Higher On-admission Serum Triglycerides Predict Less Severe Disability and Lower All-cause Mortality after Acute Ischemic Stroke
Conclusions: These data suggest that higher fasting TGs on-admission predict less severe disability, reduced disability progression, and all-cause mortality in patients with acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - April 16, 2012 Category: Neurology Authors: Slaven Pikija, Vladimir Trkulja, Lucija Juvan, Marija Ivanec, Dunja Dukši Tags: Original Articles Source Type: research

Long-term Adherence to National Guidelines for Secondary Prevention of Ischemic Stroke: A Prospective Cohort Study in a Public Hospital in Chile
Conclusions: The observed significant decrease in adherence to oral anticoagulation in patients with cardioembolic stroke suggests a need for the implementation of specific strategies to achieve the desired secondary prevention goals in these patients. Future research into the evaluation of other factors that could be associated with the lack of adherence to these guidelines, measurements of therapeutic goals, and new therapeutic strategies that are easier to use and that are associated with less risk could improve the prognosis of these patients.
Source: Journal of Stroke and Cerebrovascular Diseases - May 15, 2013 Category: Neurology Authors: Paula Muñoz-Venturelli, Claudio Sacks, Eva Madrid, Pablo M. Lavados Tags: Original Articles Source Type: research

Overenthusiastic stroke risk factor modification in the over-80s: Are we being disingenuous to ourselves, and to our oldest patients?
Statins and antihypertensive therapy are widely used in our oldest patients (ie, those aged over 80 years). The epidemiology suggests that, by this age, hypertension is not an attributable risk factor for stroke, and hypercholesterolaemia has little effect on stroke risk overall. The largest trials of antihypertensive therapy and statins in this age group show at best a marginal clinical reduction in stroke and very modest clinical reductions in other cardiovascular end points. Older patients have very diverse views on the relative importance of stroke and death as end points, and these differ from physicians’ views....
Source: Evidence-Based Medicine - July 18, 2014 Category: Internal Medicine Authors: Byatt, K. Tags: Geriatric medicine, Clinical trials (epidemiology), Editor's choice, Press releases, Drugs: cardiovascular system, Stroke, Hypertension, Ethics, Legal and forensic medicine, Lipid disorders Perspective Source Type: research

Acute stroke chameleons in a university hospital: Risk factors, circumstances, and outcomes
Conclusions: AIS are missed in patients with younger age with a lower cerebrovascular risk profile and may be masked by other acute conditions. Patients with chameleons present more often with milder strokes or coma, fewer focal signs and cerebellar strokes, and have higher disability and mortality rates at 12 months. These findings may be used to raise awareness in emergency departments to recognize and treat such patients appropriately.
Source: Neurology - August 10, 2015 Category: Neurology Authors: Richoz, B., Hugli, O., Dami, F., Carron, P.-N., Faouzi, M., Michel, P. Tags: Other cerebrovascular disease/ Stroke, Natural history studies (prognosis), Risk factors in epidemiology, Infarction ARTICLE Source Type: research

PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites Original Articles
Conclusions— PCSK9 LOF variants were associated with lower LDL-C and coronary heart disease incidence. PCSK9 LOF variants were not associated with stroke risk.
Source: Circulation: Cardiovascular Genetics - August 2, 2017 Category: Cardiology Authors: Kent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., Harris, T. B., Howard, G., Irvin, M. R., Judd, S. E., Jukema, J. W., Lange, L., Levitan, E. B., Li, X., Liu, Tags: Lipids and Cholesterol, Genetic, Association Studies, Myocardial Infarction, Meta Analysis, Cerebrovascular Disease/Stroke Original Articles Source Type: research

Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence Clinical Sciences
Conclusions—The composite risk of stroke and transient ischemic attack reduced in the postrandomized LDL cholesterol level of 80 to 100 mg/dL after adjusting for statin usage.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00221104.
Source: Stroke - March 26, 2018 Category: Neurology Authors: Naohisa Hosomi, Kazuo Kitagawa, Yoji Nagai, Yoko Nakagawa, Shiro Aoki, Tomohisa Nezu, Tatsuo Kagimura, Hirofumi Maruyama, Hideki Origasa, Kazuo Minematsu, Shinichiro Uchiyama, Masayasu Matsumoto Tags: Lipids and Cholesterol, Secondary Prevention, Treatment Original Contributions Source Type: research

Statin Therapy in Ischemic Stroke Models: A Meta-Analysis
AbstractStatins, drugs known for lipid lowering capabilities and reduction of cardiovascular disease, have demonstrated neuroprotective effects following ischemic stroke in retrospective clinical and animal studies. However, dosing (methods, time, type of statin, and quantity) varies across studies, limiting the clinical applicability of these findings. Furthermore, a comprehensive review of statins in edema and blood-brain barrier (BBB) breakdown is needed to provide insight on diverse, less explored neuroprotective effects. In the present study, we conduct a meta-analysis of publications evaluating statin administration ...
Source: Translational Stroke Research - December 1, 2019 Category: Neurology Source Type: research

Use of statins for the secondary prevention of stroke: are we respecting the scientific evidences?
Background: Stroke accounts for approximately as 5.0% of disability-adjusted years of life and 10.0% of all deaths worldwide. Secondary stroke prevention in surviving individuals, which includes the use of statins, reduces atherothrombotic stroke recurrence, complications and mortality. The present study aimed to characterize the Brazilian population with stroke history and estimate the prevalence of statin use as secondary prevention.Methods: This is a population-based cross-sectional study conducted in Brazilian urban areas.
Source: Journal of Stroke and Cerebrovascular Diseases - July 15, 2020 Category: Neurology Authors: Jo ão Paulo Vilela Rodrigues, Lucas Borges Pereira, Maria Olívia Barboza Zanetti, Andréia Turmina Fontanella, Nereida Kilza da Costa Lima, Sotero Serrate Mengue, Leonardo Régis Leira Pereira Source Type: research

Treatment with Atorvastatin During Vascular Remodeling Promotes Pericyte-Mediated Blood-Brain Barrier Maturation Following Ischemic Stroke
This study examined our hypothesis that, during vascular remodeling after stroke, treatment with atorvastatin could facilitate BBB maturation in remodeling vasculature in ischemic brain. Adult spontaneously hypertensive rats underwent middle cerebral artery occlusion with reperfusion (MCAO/RP). Atorvastatin, at dose of 3  mg/kg, was delivered daily starting at 14 days after MCAO/RP onset for 7 days. The rats were studied at multiple time points up to 8 weeks with multimodal-MRI, behavior tests, immunohistochemistry, and biochemistry. The delayed treatment of atorvastatin significantly reduced infarct size and BBB perme...
Source: Translational Stroke Research - January 9, 2021 Category: Neurology Source Type: research

High Cholesterol Levels Are Associated with Improved Long-term Survival after Acute Ischemic Stroke
Conclusions: High admission cholesterol may be associated with increased long-term survival after IS. Future studies on the temporal profile of cholesterol levels and stroke outcome would be of interest.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2013 Category: Neurology Authors: Ioanna Markaki, Ulrik Nilsson, Konstantinos Kostulas, Christina Sjöstrand Tags: Original Articles Source Type: research

Dose-Related Effects of Statins on Symptomatic Intracerebral Hemorrhage and Outcome After Thrombolysis for Ischemic Stroke Clinical Sciences
Conclusions— We observed an association between increasing dose of statin use and risk of sICH after intravenous thrombolysis. Nevertheless, there was an overall beneficial effect of previous statin use on favorable 3-month outcome.
Source: Stroke - January 27, 2014 Category: Neurology Authors: Scheitz, J. F., Seiffge, D. J., Tutuncu, S., Gensicke, H., Audebert, H. J., Bonati, L. H., Fiebach, J. B., Tranka, C., Lyrer, P. A., Endres, M., Engelter, S. T., Nolte, C. H. Tags: Other Treatment, Thrombolysis Clinical Sciences Source Type: research

Effect of Simvastatin on MMPs and TIMPs in Human Brain Endothelial Cells and Experimental Stroke
Abstract Clinical studies demonstrated favorable effects of statins in stroke beyond lipid-lowering effects. In acute stroke, the disruption of the blood–brain barrier (BBB) is mediated by matrix metalloproteinases (MMPs). A modified MMP metabolism may account for the beneficial effects of statins. Cultured human brain microvascular endothelial cells (BMECs) were pretreated with simvastatin and subjected to oxygen glucose deprivation (OGD). Gene expression and protein secretion of MMP-2 and MMP-9 and the tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 were measured by quantitative real-time polymerase ...
Source: Translational Stroke Research - December 5, 2014 Category: Neurology Source Type: research

Letter by Scheitz et al Regarding Article, “Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)” Letter to the Editor
Source: Stroke - February 26, 2018 Category: Neurology Authors: Jan F. Scheitz, Kennedy R. Lees, Matthias Endres Tags: Cerebrovascular Disease/Stroke, Intracranial Hemorrhage, Ischemic Stroke, Neuroprotectants Letters to the Editor Source Type: research

Response by Yoshimura et al to Letter Regarding Article, “Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)” Letter to the Editor
Source: Stroke - February 26, 2018 Category: Neurology Authors: Shinichi Yoshimura, Kazutaka Uchida, Takeshi Morimoto Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke, Neuroprotectants Letters to the Editor Source Type: research

Statin Use and the Risk of Dementia in Patients with Stroke: A Nationwide Population-Based Cohort Study
Background: Patients with stroke have an increased risk of  dementia. Some studies have found that statin use might lower the risk of incident dementia; however, there is still a lack of data from patients with stroke. Therefore, the aim of our study was to investigate the impact of statin use on the risk of dementia in patients with stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - August 6, 2018 Category: Neurology Authors: Mei-Lien Pan, Chien-Chi Hsu, Yi-Min Chen, Hui-Kung Yu, Gwo-Chi Hu Source Type: research